Stock of the Day: What’s Ahead for Vascular Biogenics Ltd After Today’s Big Decline?

Stock of the Day: What's Ahead for Vascular Biogenics Ltd After Today's Big Decline?

The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) is a huge mover today! About 95,080 shares traded hands. Vascular Biogenics Ltd (NASDAQ:VBLT) has risen 47.10% since April 18, 2016 and is uptrending. It has outperformed by 42.67% the S&P500.
The move comes after 8 months negative chart setup for the $129.78 million company. It was reported on Nov, 18 by Barchart.com. We have $4.11 PT which if reached, will make NASDAQ:VBLT worth $18.17M less.

Vascular Biogenics Ltd (NASDAQ:VBLT) Ratings Coverage

Out of 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vascular Biogenics has been the topic of 8 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained Vascular Biogenics Ltd (NASDAQ:VBLT) on Friday, October 23 with “Buy” rating. JMP Securities upgraded Vascular Biogenics Ltd (NASDAQ:VBLT) on Monday, September 21 to “Mkt Outperform” rating. The firm has “Buy” rating by Roth Capital given on Monday, August 24. Roth Capital maintained Vascular Biogenics Ltd (NASDAQ:VBLT) on Monday, September 28 with “Buy” rating. The stock has “Overweight” rating given by Piper Jaffray on Monday, November 9. The company was initiated on Monday, September 21 by Chardan Capital Markets. The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) has “Buy” rating given on Tuesday, June 28 by H.C. Wainwright.

According to Zacks Investment Research, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.”

More recent Vascular Biogenics Ltd (NASDAQ:VBLT) news were published by: Globenewswire.com which released: “Vascular Biogenics Ltd. Closes $24 Million Registered Direct Offering” on June 16, 2016. Also Investorplace.com published the news titled: “Vascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial” on June 06, 2016. Marketwatch.com‘s news article titled: “Plus the latest data from Realtor.com on 21 home markets across the US” with publication date: October 02, 2014 was also an interesting one.

VBLT Company Profile

Vascular Biogenics Ltd., incorporated on January 31, 2000, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company’s lead product candidate, VB-111(ofranergene obadenovec), is a gene biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule that demonstrated efficacy in reducing vascular inflammation in a Phase II sub-study in psoriatic patients with cardiovascular risk.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment